Schedule 13D ownership disclosure

BOLT BIOTHERAPEUTICS INC

Common Stock, $0.00001 par value · CUSIP: 097702203

Event date: 2026-02-24

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Nan Fung Group Holdings LimitedReported CIK 0001782539

    Shares: 87,486 · Class: 4.6%

  • NF Investment Holdings Limited

    Shares: 87,486 · Class: 4.6%

  • Pivotal bioVenture Partners Fund I, L.P.Reported CIK 0001695076

    Shares: 52,556 · Class: 2.7%

  • Pivotal bioVenture Partners Fund I G.P., L.P.Reported CIK 0001752862

    Shares: 52,556 · Class: 2.7%

  • Pivotal bioVenture Partners Fund I U.G.P. Ltd.

    Shares: 52,556 · Class: 2.7%

  • Pivotal Partners Ltd

    Shares: 52,556 · Class: 2.7%

  • Pivotal Life Sciences Holdings Limited

    Shares: 52,556 · Class: 2.7%

  • Nan Fung Life Sciences Holdings Limited

    Shares: 82,486 · Class: 4.3%

  • Permwell Management Limited

    Shares: 5,000 · Class: 0.3%

  • NFLS Beta Limited

    Shares: 29,930 · Class: 1.6%

  • NFLS Platform Holdings Limited

    Shares: 29,930 · Class: 1.6%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001012975-26-000212
Form type
SCHEDULE 13D/A
Filer
Bolt Biotherapeutics, Inc.
CIK
CIK 1641281
Filed
Feb 26, 2026
Reporting period
Feb 24, 2026
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub